OHSU

IRB #

IRB00010201

Title

Phase I/II Study of the Safety and Efficacy of the AKT Inhibitor GSK2141795 in Combination with the BRAF Inhibitor Dabrafenib in Patients with BRAF Mutant Cancer

Principal Investigator

Matthew Taylor

Study Purpose

To assess the safety of dabrafenib and GSK2141795 (the study drug) and determine the optimal dose of the study drug in patients with BRAF mutant metastatic melanoma.

Medical Condition(s)

Melanoma with BRAF mutations

Eligibility Criteria

1. BRAF mutant metastatic melanoma.
2. Melanoma that has progressed after prior therapy.
3. Must be willing to submit tumor tissue from a previous biopsy or undergo a biopsy to obtain fresh tissue for research studies.
4. Other criteria apply.

Age Range

18 - 100

Healthy Volunteers Needed

No

Duration of Participation

Until your cancer gets worse or you develop unacceptable side effects

Minors Included

No

Contact

Knight Clinical Trials Information Line
503-494-1080

Sponsor

SWOG

Recruitment End

12/31/2014

Compensation Provided

No


Go Back